Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical ...

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...

The following is a summary of “Clinical significance and pro-oncogenic function of DBF4 in clear cell renal cell carcinoma,” published in the January 2025 issue of Urology by Chen et al. Clear cell ...

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

The FDA has accepted Merck's (MRK) supplemental NDA with priority review for its drug Welireg for the treatment of a rare ...

The Duluth East dance team held their annual dance show on Wednesday, recognizing seniors and raising money for a teammate ...

In this Review, the authors provide a comprehensive historical overview of the advancements in the understanding of biology and genetics of paediatric renal non-Wilms tumours, and discuss how this ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Basketball Hall of Famer Dwyane Wade talked for the first time yesterday about his surgery for kidney cancer in December 2023.

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 7,680,000 shares, an ...